Brain Health Support Program

Not Applicable

Completed

• Conditions: Mild Cognitive Impairment; Subjective Cognitive Impairment; Cognitive Change; Dementia Prevention
• Interventions: Other: Brain Health PRO

• Registration Number: NCT05347966
• Lead Sponsor: Baycrest

Brief Summary

The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP, or CTU) is a comprehensive and innovative program aimed to develop, implement and evaluate an interactive and compelling online educational Brain Health Support Program (BHSP) intervention, called Brain Health PRO (BHPro), with potential to positively influence dementia literacy, lifestyle risk factors, and scale-up to reach the broader Canadian public; enroll and retain a community-dwelling Platform Trial Cohort (PTC) of individuals at risk of dementia; and support an open platform trial to test a variety of multidomain interventions that might further benefit individuals at risk of dementia.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-06
• Study First Submitted: 2022-04-14
• Study First Submitted QC: 2022-04-22
• Study First Posted: 2022-04-27
• Primary Completion: 2024-01-05
• Study Completion: 2024-04-19
• Results First Submitted: 2025-02-27
• Status Verified: 2025-04
• Results First Submitted QC: 2025-04-30
• Last Update Submitted: 2025-04-30
• Results First Posted: 2025-05-02
• Last Update Posted: 2025-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 354

Inclusion Criteria

1. Completion and documentation of the electronic Informed Consent Process (from the participant)

2. Sufficient proficiency in English or French to undergo remote clinical and neuropsychological assessment and participate in an online educational program.

3. Technical ability to participate in an online educational program and remote assessments (i.e. computer and internet access; ability to send and receive emails; ability to complete remote assessments)

4. Sufficient vision and hearing to participate in online educational program and to undergo remote clinical and neuropsychological testing

5. Ability to sit comfortably for a period of about 30 minutes

6. Ages 60-85

7. Meets criteria for No Dementia and meet criteria [according to Canadian Consortium on Neurodegeneration in Aging (CCNA) Criteria, Appendix 1] of one of the following:

   • Cognitively Unimpaired (CU)
   • Cognitively Unimpaired plus Subjective Cognitive Impairment (CU + SCI)
   • Mild Cognitive Impairment (MCI)

8. AND Classified as being at increased risk of dementia based on at least one of the following:

   • First-degree family history of dementia
   • Self-Reported or documented current and/or history at midlife (45-60 years) on any of the following lifestyle risk factors:

   Hypertension (documented Systolic Blood Pressure > 140 mm Hg; OR physician diagnosis of hypertension; OR treatment for hypertension; OR other approaches to treatment (e.g. diet, exercise)) Hypercholesterolemia (documented total cholesterol > 6.5 mmol/L; OR physician diagnosis of hypercholesterolemia; OR treatment for hypercholesterolemia; OR other approaches to treatment (e.g. diet, exercise) Body Mass Index > 30 kg/m2 (derived from NIH Metric BMI Calculator) Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week)

9. Participant has a family physician or other healthcare provider and agrees to have the provider notified of participation in the study and incidental or other findings that may be clinically significant

Exclusion Criteria

1. Participants who, in the opinion of the investigator, are not able to complete trial procedures remotely or adhere to the schedule of study assessments will be excluded from study participation.
2. Individuals where English or French is not sufficiently proficient for remote clinical assessment, neuropsychological testing and participation in an online educational program.
3. Participants who do not have sufficient vision and hearing for remote clinical assessment, neuropsychological testing participation in an online educational program
4. Individuals who do not have the technical ability to participate in an online educational program. Technical ability is defined as having computer and internet access; ability to send and receive emails; ability to participate in remote assessments
5. Individuals who have a clinical diagnosis of Dementia
6. Clinical Dementia Rating (CDR; telephone/video-conference administration) Score of >1
7. Total Score on the Montreal Cognitive Assessment (MoCA; video-conference administration) <13

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Brain Health PRO	Brain Health PRO	-

Primary Outcome Measures

Name	Time	Method
Change in Dementia Literacy From Baseline to Month 12	12 months	The primary outcome will be change in dementia literacy following participation in the study, as measured by the Alzheimer's Disease Knowledge Scale (ADKS). The ADKS is designed to assess knowledge about Alzheimer's Disease (AD) among laypeople, patients, caregivers, and professionals. This self-report questionnaire contains 30 true/false items. The total score is the sum of the scores from the 30 items, which is quantitative and ranges from 0-30, with a higher score indicating better knowledge about AD. To aide interpretation, change in ADKS scores were converted to standardized change scores by dividing the covariate-adjusted least squares mean change by the baseline standard deviation. The results reported are the standardized change on the scale from baseline to month 12. The converted to standardized score range is -10.81 to +10.81. The greater the positive change in score, the greater the increase in knowledge of dementia.

Secondary Outcome Measures

Name	Time	Method
Change in Self-efficacy From Baseline to Month 12	12 months	Change in self-efficacy following participation in the study, as measured by the General Self-Efficacy Scale (GSE). The GSE measures perceived competence in dealing with a range of stressful or challenging situations. This self-report questionnaire contains 10-items, each rated on a 4-point scale (not true at all, hardly true, moderately true, exactly true). The total score is the sum of the scores for the 10 items, which is quantitative and ranges from 10-40, with a higher score indicating more self-efficacy. To aide interpretation, change in GSE scores were converted to standardized change scores by dividing the covariate-adjusted least squares mean change by the standard deviation. The results reported are the standardized change on the scale from baseline to month 12. The converted to standardized score range is -7.39 to +7.39. The greater the change in score, the greater the increase in self-efficacy.
To Evaluate Usability of BHPro	12 months	Based on System Usability Scale (SUS). The SUS is an 11-item questionnaire with 5-point Likert scale. The total raw score ranges from 0-43 with a higher score indicating greater usability and satisfaction with Brain Health Pro.
Number of Chapters Completed on BHPro	12 months	To evaluate engagement with Brain Health PRO, the number of chapters completed on BHPro was calculated. There is a total of 180 chapters (181 when orientation chapter is included) that are available on BHPro. The program allows participants to view 160 chapters (excluding the orientation chapter) when reaching week 45 (the intended length of the BHPro program). After 45 weeks, the remaining chapters that were still locked will become accessible for users interested in viewing all the program content. The range of chapters that could be completed on Brain Health PRo by participants is 1-181, with a higher number indicating higher engagement with the program.
To Evaluate User Acceptance of BHPro With the Technology Acceptance Model Questionnaire (TAMQ).	12 months	Based on Technology Acceptance Model Questionnaire. The TAMQ is a 20-item questionnaire (adapted for BHPro) with 7-point scale. The total score ranges between 0-120, with a higher score indicating greater acceptance and satisfaction with BHPro.

Trial Locations

Locations (7)

Cape Breton University; 🇨🇦 Cape Breton, Nova Scotia, Canada

University of British Columbia; 🇨🇦 Vancouver, British Columbia, Canada

CRIUGM/ CIUSSS du Centre-Sud-de-l'Île-de-Montréal; 🇨🇦 Montréal, Quebec, Canada

University of New Brunswick; 🇨🇦 Fredericton, New Brunswick, Canada

Gait and Brain Laboratory, Parkwood Research Institute; 🇨🇦 London, Ontario, Canada

Cognitive Clinical Research Group, Parkwood Research Institute; 🇨🇦 London, Ontario, Canada

Baycrest; 🇨🇦 Toronto, Ontario, Canada